STAAR Surgical Begins Marketing STAARVISC(TM) II STAARVISC II gives STAAR Surgical Market Opportunity

Apr 27, 2001, 01:00 ET from STAAR Surgical Company

    MONROVIA, Calif., April 27 /PRNewswire/ -- STAAR Surgical Company
 (Nasdaq:   STAA) will begin to market STAARVISC(TM) II, sodium hyaluronate
 viscoelastic. STAARVISC II is a clear, viscous substance used to protect
 delicate tissues inside the eye during cataract procedures and other
 ophthalmic anterior and posterior procedures. STAAR licensed the right to sell
 STAARVISC II from Anika Therapeutics Inc. (Nasdaq:   ANIK) of Woburn,
 Massachusetts who manufactures the product.  Anika Therapeutics has announced
 that it received Pre-Market Approval (PMA) for STAARVISC II from the United
 States Food and Drug Administration.
     According to David Bailey, president and chairman of STAAR Surgical
 Company, "STAARVISC II helps round out our existing cataract line including
 the intraocular lenses (IOLs), STAARPacks and the SonicWAVE(TM)
 Phacoemulsification system. The addition of STAARVISC II allows the Company to
 offer a complete product package for the cataract procedure. Referred to as
 procedural marketing in the industry, we now have a distinct opportunity to
 create a package contract at a single price for facilities that want all of
 their ophthalmic surgical devices through one vendor."
     Viscoelastic substances are routinely used in cataract surgery and other
 surgical anterior segment procedures.  The main reason for the use of
 viscoelastics is to prevent endothelial damage.  The viscoelastic coats both
 the lens and the endothelium, essentially acting as a cushion between the two.
 In addition, the solution props the tissue to maintain the anterior chamber of
 the eye during the cataract procedure.
     STAARVISC II is a cohesive viscoelastic substance providing important
 properties and functions to procedures including excellent clarity, ability to
 prop tissue versus moving tissue, anterior chamber maintenance, easy IOL
 positioning, and easy removal from the eye.  STAARVISC II is indicated for use
 as a surgical aid in ophthalmic anterior and posterior segment procedures
 including cataract, corneal transplant, glaucoma filtering, and retinal
 reattachment.
     Founded in 1982, STAAR Surgical Company develops, manufactures and
 globally distributes minimally invasive medical devices for use in refractive,
 cataract and glaucoma surgery. The Company's principal product line includes
 foldable intraocular lenses, which are used as replacements for the natural
 lens in cataract procedures. STAAR also markets two products internationally:
 an Implantable Contact Lens(TM), which is a refractive lens for the treatment
 of nearsightedness and farsightedness and the AquaFlow(TM) collagen glaucoma
 drainage device.  STAAR's products are distributed throughout European Union
 and in other parts of the world under CE mark with the exception of the Toric
 ICL(TM) and the 3-piece Collamer(TM) IOL.
     For additional information, about STAAR Surgical, visit the Company's web
 site at http://www.STAAR.com or www.irbyctc.com . You may wish to contact
 David Bailey, President, STAAR Surgical, or John Santos, Chief Financial
 Officer, STAAR Surgical, at (626) 303-7902.  To contact Bill Roberts,
 President, CTC, Inc., or Ellen Geron, CTC Inc., please call  (937) 434-2700.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X69896763
 
 

SOURCE STAAR Surgical Company
    MONROVIA, Calif., April 27 /PRNewswire/ -- STAAR Surgical Company
 (Nasdaq:   STAA) will begin to market STAARVISC(TM) II, sodium hyaluronate
 viscoelastic. STAARVISC II is a clear, viscous substance used to protect
 delicate tissues inside the eye during cataract procedures and other
 ophthalmic anterior and posterior procedures. STAAR licensed the right to sell
 STAARVISC II from Anika Therapeutics Inc. (Nasdaq:   ANIK) of Woburn,
 Massachusetts who manufactures the product.  Anika Therapeutics has announced
 that it received Pre-Market Approval (PMA) for STAARVISC II from the United
 States Food and Drug Administration.
     According to David Bailey, president and chairman of STAAR Surgical
 Company, "STAARVISC II helps round out our existing cataract line including
 the intraocular lenses (IOLs), STAARPacks and the SonicWAVE(TM)
 Phacoemulsification system. The addition of STAARVISC II allows the Company to
 offer a complete product package for the cataract procedure. Referred to as
 procedural marketing in the industry, we now have a distinct opportunity to
 create a package contract at a single price for facilities that want all of
 their ophthalmic surgical devices through one vendor."
     Viscoelastic substances are routinely used in cataract surgery and other
 surgical anterior segment procedures.  The main reason for the use of
 viscoelastics is to prevent endothelial damage.  The viscoelastic coats both
 the lens and the endothelium, essentially acting as a cushion between the two.
 In addition, the solution props the tissue to maintain the anterior chamber of
 the eye during the cataract procedure.
     STAARVISC II is a cohesive viscoelastic substance providing important
 properties and functions to procedures including excellent clarity, ability to
 prop tissue versus moving tissue, anterior chamber maintenance, easy IOL
 positioning, and easy removal from the eye.  STAARVISC II is indicated for use
 as a surgical aid in ophthalmic anterior and posterior segment procedures
 including cataract, corneal transplant, glaucoma filtering, and retinal
 reattachment.
     Founded in 1982, STAAR Surgical Company develops, manufactures and
 globally distributes minimally invasive medical devices for use in refractive,
 cataract and glaucoma surgery. The Company's principal product line includes
 foldable intraocular lenses, which are used as replacements for the natural
 lens in cataract procedures. STAAR also markets two products internationally:
 an Implantable Contact Lens(TM), which is a refractive lens for the treatment
 of nearsightedness and farsightedness and the AquaFlow(TM) collagen glaucoma
 drainage device.  STAAR's products are distributed throughout European Union
 and in other parts of the world under CE mark with the exception of the Toric
 ICL(TM) and the 3-piece Collamer(TM) IOL.
     For additional information, about STAAR Surgical, visit the Company's web
 site at http://www.STAAR.com or www.irbyctc.com . You may wish to contact
 David Bailey, President, STAAR Surgical, or John Santos, Chief Financial
 Officer, STAAR Surgical, at (626) 303-7902.  To contact Bill Roberts,
 President, CTC, Inc., or Ellen Geron, CTC Inc., please call  (937) 434-2700.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X69896763
 
 SOURCE  STAAR Surgical Company